Invivo Therapeutics (NVIV) Earning Somewhat Positive News Coverage, Report Shows

Media coverage about Invivo Therapeutics (NASDAQ:NVIV) has trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Invivo Therapeutics earned a news impact score of 0.13 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.3499186378252 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Invivo Therapeutics (NVIV) traded up $0.01 during midday trading on Friday, hitting $0.52. The stock had a trading volume of 147,148 shares, compared to its average volume of 205,245. The firm has a market cap of $17.82, a PE ratio of -0.61 and a beta of 2.71. Invivo Therapeutics has a one year low of $0.45 and a one year high of $4.60. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.06 and a quick ratio of 5.06.

COPYRIGHT VIOLATION WARNING: “Invivo Therapeutics (NVIV) Earning Somewhat Positive News Coverage, Report Shows” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/18/invivo-therapeutics-nviv-earning-somewhat-positive-news-coverage-report-shows.html.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

Insider Buying and Selling by Quarter for Invivo Therapeutics (NASDAQ:NVIV)

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply